A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1500 participants.
Also called NCT03811561
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,500 participants
- Sponsor
- Registry
-
NCT03811561 -
2017-003619-20
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Brazil, Bulgaria, Canada, Czechia, Germany, Greece, India, Israel, Latvia, Mexico, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03811561. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-08 (actual); primary completion 2027-11-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
- Acronym
- FOCUS
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Placebo (semaglutide)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct03811561- Content hash
9590af99a4d588adc220aa307547dffaf822533dc1c26f69fb5c8061d94e4a99